Biogen (BIIB) Tops Q4 EPS by 3c; offers outlook
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $199.71 --0%
EPS Growth %: -41.3%
Financial Fact:
Diluted earnings per share attributable to Biogen Idec Inc.: 4.71
Today's EPS Names:
REPL, MOGU, JFIN, More
EPS Growth %: -41.3%
Financial Fact:
Diluted earnings per share attributable to Biogen Idec Inc.: 4.71
Today's EPS Names:
REPL, MOGU, JFIN, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q4 EPS of $3.44, $0.03 better than the analyst estimate of $3.41. Revenue for the quarter came in at $2.45 billion versus the consensus estimate of $2.41 billion.
GUIDANCE:
Biogen sees FY2025 EPS of $15.25-$16.25, versus the consensus of $16.24.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
- AEVEX wins $15.2M contract option for California wildfire program
- AeroVironment restates quarterly financials, citing $89M goodwill error
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
